Search Results Summary:
-
Product type 4 – Codependent technologies
Product type 4 – Codependent technologies
pbac.pbs.gov.au/product-type-4-codependent-technologies.html
Page last updated: September 2016
-
2.4 Trial characteristics
the dose or treatment regimen, including the use of concomitant treatments, is supported by high-quality clinical practice guidelines and by the product information for each of the medicines. Justify where
indications, or contains two active components (see Product type 1) that affect two distinct indications, establish noninferiority for the primary and most patient-relevant outcomes for both indications.
pbac.pbs.gov.au/section-2/2-4-trial-characteristics.html
Page last updated: September 2016
-
4.6 Identification, estimation and reduction of uncertainty
product is tracked in a defined patient population over a specified period of time and the level or continuation of reimbursement is based on the health and economic outcomes achieved’. 49
pbac.pbs.gov.au/section-4/4-6-identification-estimation-and-reduction-of-uncertainty.html
Page last updated: September 2016
